彭鑫，助理教授、博士生導師、研究員。2015年獲得天津醫科大學學士學位，2020年獲得天津醫科大學博士學位（2019年至2020年，先后作為MD安德森癌癥中心系統生物學系及生物信息學系聯培博士）。獲得天津市自然科學二等獎，天津市“海河英才”創新創業大賽博士后揭榜領題賽銅獎。入選中國科協“青年人才托舉工程”項目。主持6項國家級及省部級科研課題。 院校引進人才，2024年加入院校。曾于2021年至2024年在天津醫科大學任博士后；2020年至2021年在MD安德森癌癥中心任博士后。

長期從事以基于多組學數據挖掘結合實驗篩選平臺，進行腫瘤新藥研發與精準治療研究。涉及抗腫瘤藥物靶點發現及合成、DNA損傷療法增敏生物標志物篩選及聯用策略開發等關鍵科學問題。作為核心研究人員開發的新型pan-PI3K抑制劑KTC1101在MedChemExpress公司商業化轉化。發表SCI論文18篇，其中第一或通訊作者文章7篇，如Mol Cancer（2篇），Signal Transduct Target Ther，Adv Sci（2篇），Cancer Res，J Exp Clin Cancer Res等，合作文章發表在Cancer Cell等期刊。他引次數588，單篇最高他引次數158，H指數16。

久久综合九色欧美综合狠狠_伊人热热久久原色播放WWW_成A人片亚洲日本久久_久久不见久久见免费影院www日本_97久久精品人人做人人爽,又色又爽又黄的视频在线观看,狼群影院视频在线观看高清版,亚洲AV无码精品网站性色,国产乱码久久久久久红粉影视,精品国产乱码久久久久久一区二区,国产精品免费视频网站,国产A级毛片久久久久久精品,一级特黄高清aaaa大片,亚洲中文字幕欧美一区,久久精品国产99久久狂热,黑人巨大精品欧美_黑人巨大精品欧美黑寡妇_黑人巨大精品欧美一区二区_黑人巨大精品欧美一区二区免费_黑人巨大跨种族video_黑人巨大无码中文字幕无码_黑人巨茎大战俄罗斯美女_黑人巨茎大战俄罗斯美女,中文字幕av不卡|亚洲欧美国产另类|天天干在线播放|日韩黄视频|欧美七区|可以免费看毛片的网站|黄色片在线|国产精品96久久久久久

1. Xin Peng#*, Yingying Wang#, Zixiang Yu#, Shaolu Zhang, Zhenxing Zhong, Yongzhe Wang, Shanshan Liu, Kailin Wang, Christophe Nicot*, Francois X. Claret*, Dexin Kong*. Jab1 regulates HRR mRNA stability to modulate PARP inhibitor sensitivity in triple-negative breast cancer. Mol Cancer. 2025, 24(1):217. (IF=33.9)

2. Xin Peng#, Xin Huang#, Talal Ben Lulu#, Wenqing Jia, Shaolu Zhang, Limor Cohen, Shengfan Huang, Jindian Fan, Xi Chen, Shanshan Liu, Yongzhe Wang, Kailin Wang, Sho Isoyama, Shingo Dan, Feng Wang, Zhe Zhang*, Moshe Elkabets*, Dexin Kong*. A novel pan-PI3K inhibitor KTC1101 synergizes with anti-PD-1 therapy by targeting tumor suppression and immune activation. Mol Cancer. 2024, 23(1):54. (IF=41.4)

3. Xin Peng#, Xin Huang#, Shaolu Zhang#, Naixin Zhang, Yingying Wang, Zixiang Yu, Xi Chen, Moshe Elkabets, Francois X. Claret, Feng Wang, Ning Ji*, Yuxu Zhong*, Dexin Kong*. Sequential inhibition of PARP and BET as a rational therapeutic strategy for glioblastoma. Adv Sci. 2024, 11(30):2307747. (IF=14.1)

4. Xin Peng#, Yingying Wang#, Shaolu Zhang#, Zhennan Tao, Yuxiang Dai, Francois X. Claret, Moshe Elkabets, Hou-Wen Lin*, Zhe-Sheng Chen*, Dexin Kong*. Stellettin B renders glioblastoma vulnerable to poly (ADP-ribose) polymerase inhibitors via suppressing homologous recombination repair. Signal Transduct Target Ther. 2023, 8(1):119. (IF=38.104)

5. Xin Peng, Shaolu Zhang, Yingying Wang, Zhicheng Zhou, Zixiang Yu, Zhenxing Zhong, Liang Zhang, Zhe-Sheng Chen, Francois X. Claret, Moshe Elkabets, Feng Wang, Fan Sun, Ran Wang*, Han Liang*, Hou-Wen Lin*, Dexin Kong*. Stellettin B sensitizes glioblastoma to DNA-damaging treatments by suppressing PI3K-mediated homologous recombination repair. Adv Sci. 2023, 10(3):2205529. (IF=17.521)

6. Xin Peng#, Shaolu Zhang#, Wenhui Jiao, Zhenxing Zhong, Yuqi Yang, Francois X. Claret, Moshe Elkabets, Feng Wang, Ran Wang*, Yuxu Zhong*, Zhe-Sheng Chen*, Dexin Kong*. Hydroxychloroquine synergizes with the PI3K inhibitor BKM120 to exhibit antitumor efficacy independent of autophagy. J Exp Clin Cancer Res. 2021, 40(1):374. (IF=11.663)

7. Shaolu Zhang#, Xin Peng#, Xiaofei Li, Hongyan Liu, Baoquan Zhao, Moshe Elkabets, Yao Liu, Wei Wang, Ran Wang*, Yuxu Zhong*, Dexin Kong*. BKM120 sensitizes glioblastoma to the PARP inhibitor rucaparib by suppressing homologous recombination repair. Cell Death Dis. 2021, 12(6):546. (IF=9.685)